Apyx Medical financials
$2.60+4.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.9M | $12.5M | $19.2M | $12.9M | $11.4M | $9.4M | $14.2M | $11.5M | $12.1M | $10.2M | $14.7M | $12.0M |
| Gross profit | $8.9M | $7.9M | $12.0M | $8.3M | $7.1M | $5.7M | $9.0M | $7.0M | $7.5M | $5.9M | $8.9M | $8.0M |
| Gross margin | 63.9% | 63.5% | 62.6% | 64.4% | 62.3% | 60.1% | 63.0% | 60.5% | 61.7% | 58.1% | 60.9% | 66.6% |
| Operating income | -$1.8M | -$875.0K | $11.0K | -$832.0K | -$2.6M | -$3.1M | -$3.0M | -$3.6M | -$5.5M | -$6.6M | -$5.8M | -$4.6M |
| Net income | -$3.2M | -$2.1M | -$1.3M | -$2.0M | -$3.8M | -$4.2M | -$4.6M | -$4.7M | -$6.6M | -$7.6M | -$9.6M | -$4.6M |
| Net margin | −23.4% | −16.9% | −6.8% | −15.4% | −33.2% | −44.0% | −32.5% | −40.9% | −54.0% | −74.0% | −65.5% | −38.7% |
| Diluted EPS | $-0.07 | $-0.05 | $-0.03 | $-0.05 | $-0.09 | $-0.10 | $-0.12 | $-0.14 | $-0.19 | $-0.22 | $-0.28 | $-0.13 |
| EBITDA | -$1.6M | -$673.0K | $232.0K | -$668.0K | -$2.4M | -$2.9M | -$2.9M | -$3.5M | -$5.4M | -$6.5M | -$5.6M | -$4.5M |
| Operating cash flow | -$3.5M | -$572.0K | -$2.5M | -$3.5M | -$1.2M | -$702.0K | -$2.9M | -$4.4M | -$4.3M | -$6.3M | -$2.2M | $3.7M |
| Free cash flow | -$3.6M | -$632.0K | -$2.8M | -$4.1M | -$1.5M | -$757.0K | -$3.2M | -$4.6M | -$4.6M | -$6.4M | -$2.3M | $3.5M |
| Diluted shares | 43.9M | 43.7M | 42.2M | 40.7M | 40.7M | 40.7M | 38.2M | 34.6M | 34.6M | 34.6M | 34.6M | 34.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $27.6M | $31.1M | $31.7M | $25.1M | $29.3M | $31.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $35.4M | $35.1M | $34.9M | $34.6M | $34.4M | $34.2M |
| Total assets | $61.1M | $63.0M | $66.8M | $57.4M | $58.2M | $60.2M |
| Total liabilities | $50.0M | $49.9M | $52.0M | $51.3M | $50.7M | $49.5M |
| Shareholders' equity | $11.1M | $13.1M | $14.8M | $6.1M | $7.5M | $10.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology